Key Takeaways
- Cancer follow-up is not a universal schedule of tumour markers and scans. It should reflect the original cancer, stage, treatment, current medicines, recurrence pattern, late-effect risks and the patient's general health.
- A usable plan separates five jobs: looking for recurrence or a new cancer, managing late effects, restoring function, continuing preventive and chronic-disease care, and supporting psychological and social recovery.
- Before leaving China, obtain both a treatment summary and an action-oriented follow-up plan. A pile of test reports does not tell the next clinician what was given, why a test is due or who should respond.
- Give every task an owner. The patient should know which team orders each test, who compares the images, who renews ongoing treatment and which clinician acts if a result is abnormal.
- New or rapidly worsening symptoms should be assessed on clinical urgency. Do not wait for a scheduled overseas video visit when local examination or emergency care is needed.
Content
Finishing surgery, radiation or a course of systemic therapy is a transition, not the end of cancer care. The quiet interval after treatment has several different purposes: checking for recurrence, detecting a second cancer when relevant, treating delayed toxicity, rebuilding strength and function, and resuming ordinary primary care. NCI describes follow-up as regular care that can include examination, blood work and other tests, as well as review of physical and emotional problems that may emerge months or years later.[1]
For an international patient treated in China, a sixth task matters: transferring clinical responsibility across languages, hospitals and health systems. The safest plan is not the one with the most appointments. It is the one in which each appointment has a reason, the necessary records are available, and someone is accountable for the next decision.
Start with the cancer and treatment, not a generic calendar
Follow-up frequency and testing differ by cancer type, stage, treatment and overall health.[1] A schedule copied from another patient's breast, lung, bowel or blood cancer may therefore be wrong even if both patients finished treatment on the same date.
Ask the treating oncologist to write the plan in a table with these fields:
When · Responsible clinician · Visit or test · Clinical purpose · Result recipient · Action if abnormal
Exact month or date · Named department or home-country doctor · Examination, laboratory test, imaging or procedure · Recurrence surveillance, toxicity monitoring, medicine safety or routine prevention · Named team and secure channel · Review timeframe and escalation route
Avoid entries such as “regular review” or “scan as needed.” For imaging, record the body region, modality, whether contrast is expected, the previous study needed for comparison and who will compare the actual images—not only translated report text. For laboratory monitoring, list the analytes and the medicine or risk they relate to.
Tumour markers are useful in selected cancers and clinical situations, but they are not a universal recurrence screen. Likewise, more frequent CT, PET-CT or MRI is not automatically better follow-up. Ask what decision a proposed test can change and whether the schedule comes from a disease-specific guideline. Incidental findings, equivocal post-treatment changes and duplicated testing can create additional procedures without resolving the original question.
Separate the five tracks of survivorship care
1. Recurrence and new-cancer surveillance. The plan should state which symptoms, examinations and tests are relevant to the original cancer. It should also distinguish recurrence from screening for a new primary cancer. NCI notes that a second primary is different from metastatic spread and that long-term check-ups may include both the treated cancer and other cancers for which the person is at risk.[2]
2. Long-term and late effects. Some effects persist from treatment; others first appear months or years later. The risk depends on the operation performed, radiation field and dose, systemic medicines, transplant or cellular therapy, and the patient's pre-existing conditions. Possible domains include heart, lung, endocrine, bone, kidney, nerve, cognitive, fertility, sexual-health, lymphoedema and immune problems. This is a risk list, not a prediction that every survivor will develop them. NCI's late-effects resource illustrates why follow-up must be treatment-specific and why new symptoms sometimes require evaluation to distinguish toxicity from cancer.[2]
3. Function and rehabilitation. “No evidence of disease” does not mean the patient has recovered swallowing, balance, continence, arm movement, stamina or the ability to work. The plan may need oncology rehabilitation, physiotherapy, occupational or speech therapy, lymphoedema care, pain management, nutrition support or exercise advice. China's National Health Commission calls for follow-up together with functional rehabilitation, long-term nursing and nutrition support throughout cancer care.[3]
4. Preventive and chronic care. Blood pressure, diabetes, cardiovascular risk, dental health, routine vaccination and age-appropriate screening still need an owner. NCI advises survivors to continue routine primary care in addition to oncology follow-up and to stay current with screening and vaccines.[1] The oncology team should flag treatment-related exceptions—for example, timing vaccines after transplant or immune-suppressive therapy—rather than leaving the primary-care clinician to infer them.
5. Psychological, family and social recovery. Fear of recurrence, sleep problems, altered body image, sexual difficulties, fertility questions, financial pressure and return-to-work concerns are legitimate follow-up topics. A survivorship plan can include emotional, social and financial needs as well as medical surveillance.[1] Ask for referral criteria and local resources, not merely a suggestion to “stay positive.”
Treatment may continue after the “main” course ends
The end of hospital-based chemotherapy or radiation may not be the end of active treatment. Endocrine therapy, an oral targeted drug, maintenance immunotherapy, anticoagulation, bone-protective treatment or infection prophylaxis can continue for months or years. For each medicine, document:
- generic name and, when relevant, brand and formulation;
- dose, route, schedule, start date and intended duration;
- reason for treatment and criteria for holding or stopping it;
- required blood tests, blood-pressure checks, ECGs or imaging;
- clinically important interactions and missed-dose instructions;
- prescriber, renewal route and emergency contact; and
- whether an equivalent product is available in the home country.
A translated prescription alone is not enough when the home clinician needs to know prior dose reductions, toxicities or the reason a medicine was continued.
Leave China with a clinical handover, not a document dump
ASCO's treatment and survivorship forms distinguish the history of treatment—operations, medicines, doses and other therapy—from the recommended follow-up schedule, tests and possible long-term effects.[4] Before departure, request a concise bilingual summary where available and the underlying records needed for future clinical use:
- final pathology and biomarker reports, including amendments;
- operative note and discharge summary, with implants or devices identified;
- systemic-treatment protocol and the doses actually administered, including delays or reductions;
- radiation treatment summary and, if future radiation decisions may depend on it, DICOM-RT plan data;
- major complications, cultures, transfusions, allergies and adverse drug reactions;
- the latest medication reconciliation and supplies needed during travel;
- baseline and end-of-treatment imaging in original DICOM format; and
- contact details for the treating department and a consented route for record transfer.
The patient should verify that files open before travelling. Keep the signed or hospital-issued source documents separate from convenience translations, and label translations with the original document date. CDC advises people receiving care abroad to obtain complete records, share them with clinicians providing follow-up and arrange local follow-up before travel.[5]
Decide who owns each part of cross-border follow-up
Remote contact with the Chinese team can be valuable for interpreting its treatment choices or reviewing a planned scan. It does not replace a physical examination, urgent assessment, local prescribing authority or tests that must be performed near the patient.
Agree on a responsibility map before departure:
- China treating team: treatment-specific questions, clarification of operative or radiation details, and review of results it has explicitly agreed to receive;
- home oncology team: physical assessment, locally ordered surveillance, management of recurrence suspicion and coordination with other specialists;
- primary-care clinician: preventive care and chronic conditions, with treatment-related cautions supplied by oncology;
- patient or authorised caregiver: scheduling, uploading complete files and confirming that results were received; and
- emergency service: acute symptoms that cannot safely wait for either cancer team.
For every remote review, ask which portal or encrypted route to use, what file formats are accepted, whether the clinician will review images or reports, expected response time, fee, time zone and what happens during public holidays. A message marked “delivered” is not proof that a clinician has reviewed it.
Build an unscheduled-care rule
A follow-up calendar must be paired with instructions for problems between appointments. Ask the treating team to identify symptoms that deserve prompt local contact in this specific cancer and treatment context. Examples that commonly require urgent assessment include new severe breathlessness, chest pain, confusion, weakness on one side, uncontrolled bleeding, persistent vomiting with inability to drink, a rapidly worsening wound problem, or fever when the patient has been told that treatment may suppress immunity. The list must be personalised.
Do not wait for the next scheduled scan to report a persistent or worsening change. Conversely, a new symptom does not prove recurrence; local clinicians may need examination, laboratory testing or imaging to identify infection, treatment toxicity, a chronic condition or another cause. The useful handover question is: “Who should assess this first, and how quickly?”
A practical departure review
At the final China visit, the patient and companion can work through four short checks:
- Reconstruct the treatment: Can another oncologist see exactly what was diagnosed and delivered?
- Read the calendar: Does every follow-up item have a date range, purpose and owner?
- Test the transfer: Do the DICOM studies and documents open, and has the home team received them?
- Rehearse exceptions: Does the patient know whom to contact for a late result, a medicine problem, a new symptom or an emergency?
China's national cancer quality programme calls for patient education, follow-up, online consultation, complication guidance, rehabilitation and long-term care.[3] Those goals become practical only when the written plan identifies real people, dates and escalation routes.
Medical disclaimer: This article provides general educational information, not individual medical advice. Follow-up schedules and tests must be set by clinicians who know the cancer, treatment and current health. Seek immediate local care for severe or rapidly worsening symptoms.
FAQ
How often should follow-up visits happen after cancer treatment?
There is no single schedule for all cancers. Frequency depends on cancer type and stage, treatment, recurrence pattern, ongoing medicines, late-effect risk and general health.[1] Ask for the disease-specific reason behind each visit and test rather than adopting another patient's calendar.
Should every follow-up visit include tumour markers and a CT or PET-CT?
No. The useful tests vary by cancer and treatment. Ask what clinical question each test answers, what result would change management and which guideline supports the interval. Symptoms and examination may also change the plan; repeated imaging without a defined purpose can create ambiguous findings and duplicated care.
Can the treating doctor in China manage all follow-up by video after I go home?
Usually not. Remote review may help interpret treatment records or planned results, but it cannot provide every physical examination, urgent evaluation, locally regulated prescription or procedure. Arrange a home oncology clinician before departure and specify what the China team has agreed to review.[5]
What is the single most important document to obtain before leaving China?
Do not choose between a treatment summary and a follow-up plan; obtain both. The summary records what actually happened, while the plan records what comes next, including tests, late-effect risks and responsible clinicians.[4] Keep original pathology, imaging and treatment data as supporting records.
What should I do if a new symptom appears between planned visits?
Use the urgency instructions in the written plan and contact the designated local clinician. Severe or rapidly worsening symptoms need immediate local assessment, not a delayed international message. A persistent change should be evaluated, but it should not be assumed to be recurrence without clinical review.
Sources
- National Cancer Institute — Follow-Up Medical Care
- National Cancer Institute — Late Effects of Cancer Treatment
- National Health Commission of China — Action Plan to Improve the Quality of Cancer Diagnosis and Treatment
- American Society of Clinical Oncology — Cancer Treatment & Survivorship Care Plans
- US Centers for Disease Control and Prevention, Yellow Book — Medical Tourism
- National Cancer Institute — Facing Forward: Life After Cancer Treatment
Image Review
- Decision: Approved and retained as hero-reviewed.png.
- Editorial note: The illustration shows a patient, companion and clinician reviewing a continuous check-up, clinical-review and rehabilitation pathway. Its icons are schematic and should not be read as a prescribed test schedule.